| 8.93 0.38 (4.44%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.84 | 1-year : | 11.65 |
| Resists | First : | 9.28 | Second : | 9.97 |
| Pivot price | 9.36  |
|||
| Supports | First : | 8.17 | Second : | 6.79 |
| MAs | MA(5) : | 9.01  |
MA(20) : | 9.23 |
| MA(100) : | 10.12 |
MA(250) : | 9.63 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.5 |
D(3) : | 41.1 |
| RSI | RSI(14): 43.9 |
|||
| 52-week | High : | 12.4 | Low : | 5.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IMTX ] has closed above bottom band by 18.1%. Bollinger Bands are 10.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.05 - 9.11 | 9.11 - 9.16 |
| Low: | 8.49 - 8.56 | 8.56 - 8.61 |
| Close: | 8.84 - 8.95 | 8.95 - 9.03 |
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
Sun, 23 Aug 2026
Why Immatics (IMTX) Is Down 5.4% After Mixed First‑Half 2026 Loss Trends And What's Next - simplywall.st
Fri, 21 Aug 2026
Immatics N.V. (NASDAQ:IMTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Tue, 18 Aug 2026
Immatics (IMTX) awards counsel Nelson 225K share package - Stock Titan
Tue, 18 Aug 2026
Immatics Releases Q2 2026 Financial Results - AlphaStreet
Tue, 18 Aug 2026
IMTX Looks 176.9% Overvalued on GF Value™ - GuruFocus
Tue, 18 Aug 2026
Earnings Flash (IMTX) Immatics Posts Q2 Revenue 9.1M Euros, vs. FactSet Est of 10.4M Euros - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 137 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 17.5 (%) |
| Held by Institutions | 79.5 (%) |
| Shares Short | 5,050 (K) |
| Shares Short P.Month | 5,640 (K) |
| EPS | -1.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.84 |
| Profit Margin | 0 % |
| Operating Margin | -867.9 % |
| Return on Assets (ttm) | -22.5 % |
| Return on Equity (ttm) | -43.3 % |
| Qtrly Rev. Growth | -59 % |
| Gross Profit (p.s.) | -1.2 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -1.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -184 (M) |
| Levered Free Cash Flow | -111 (M) |
| PE Ratio | -4.52 |
| PEG Ratio | 0 |
| Price to Book value | 2.31 |
| Price to Sales | 32.72 |
| Price to Cash Flow | -6.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|